CA2961811C — Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Assigned to Forma Therapeutics Inc · Expires 2021-11-02 · 5y expired
What this patent protects
ABSTRACT The invention relates to inhibitors of mutant isocitrate dehydrogenase (nt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: R4 R6 u ' R1 W2W12( N /N v-- Z , B R…
USPTO Abstract
ABSTRACT The invention relates to inhibitors of mutant isocitrate dehydrogenase (nt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: R4 R6 u ' R1 W2W12( N /N v-- Z , B R2 W3 N ---......"0 FI3 (I). Date Recue/Date Received 2020-04-22
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.